These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35241549)

  • 1. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
    In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
    Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
    Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
    Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
    Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome.
    Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Horii A
    Cancer Med; 2023 Nov; 12(22):20810-20820. PubMed ID: 37902133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
    Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
    Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
    Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab.
    Takenaka Y; Takemoto N; Otsuka T; Nishio M; Tanida M; Fujii T; Hayashi K; Suzuki M; Mori M; Yamamoto Y; Uno A; Inohara H
    Jpn J Clin Oncol; 2024 Jul; 54(7):761-769. PubMed ID: 38555496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
    Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
    Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
    [No Abstract]   [Full Text] [Related]  

  • 12. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
    Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
    In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
    Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
    Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
    Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
    Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Hagiwara K; Matsuki T; Okada T; Fushimi C; Kondo T; Takahashi H; Okamoto I; Tokashiki K; Hanyu K; Kishida T; Ito T; Yamashita G; Tsukahara K; Masubuchi T; Tada Y; Momiyama K; Yaguchi R; Oridate N; Omura GO; Yamashita T
    Anticancer Res; 2024 Sep; 44(9):4057-4072. PubMed ID: 39197913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
    Yasumatsu R; Wakasaki T; Hashimoto K; Nakashima K; Manako T; Taura M; Matsuo M; Nakagawa T
    Head Neck; 2019 Aug; 41(8):2610-2618. PubMed ID: 30835919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.